Home » CSL Submits BLA for the Treatment of Congenital Bleeding
CSL Submits BLA for the Treatment of Congenital Bleeding
CSL Behring announced that it has submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) requesting approval to market its human fibrinogen concentrate in the United States for the treatment of congenital fibrinogen deficiency, a rare bleeding disorder resulting from deficiency of fibrinogen.
The Earth Times
The Earth Times
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May